 |
|
TGen researchers find genetic markers to help fight diabetes
June 16, 2009Translational Genomics Research Institute (TGen) scientists have identified five genetic biomarkers that could help lead to improved treatments, with fewer side-effects, for patients with diabetes.
TGen Senior Investigator Dr. Johanna DiStefano presented the findings in New Orleans on June 6, 2009, at the 69th Scientific Sessions of the American Diabetes Association.
"We identified genetic variants that may predict how well someone will respond to the common anti-diabetes drug, Actos," said Dr. DiStefano, Director of TGen's Diabetes, Cardiovascular & Metabolic Diseases Division. "The implications of these findings include determining which patients will best respond to the drug for the prevention or treatment of diabetes. In addition, this work lays the foundation for personalized medicine for patients with this disease."
Personalized medicine involves the rapid application of laboratory discoveries to therapies, depending on the individual genetic make-up of each patient.
A TGen-led team, working with scientists from the University of Southern California's Keck School of Medicine, investigated why as many as 30-40 percent of diabetes patients treated with thiazolidinediones (TZDs), such as Actos, fail to respond to the drug with the expected improvement in insulin sensitivity.
TZDs are a class of insulin-sensitizing drugs used to treat type 2 diabetes mellitus (T2DM). TZDs are agonists for the nuclear receptor peroxisome proliferator-activated receptor-g (PPARG). Although the exact mechanism by which TZDs act is not yet known, data indicate that TZDs improve insulin sensitivity by direct and indirect effects on adipose tissue and muscle. TZD therapy can significantly lower diabetes incidence in at-risk subjects, suggesting this treatment may be an effective means to prevent the disease.
Previously, TGen and Keck investigators found that genetic variations in the PPARG gene were associated with TZD metabolism and the biological effects of TZD, and thereby contribute to the therapeutic response associated with TZD. However, these variants did not fully account for the non-response rate, suggesting that other variants may contribute to TZD response.
To identify other variants that predict response to TZDs, TGen researchers performed a genome-wide analysis of 115,352 single nucleotide polymorphisms, or SNPs (a DNA sequence variation within the more than 3 billion base pairs in the human genome). In addition, the scientists also systematically screened 28 key genes involved in TZD metabolism or PPARG-stimulated pathways.
Of the markers examined, DiStefano and her team identified five critical markers that may predict response to TZD mono-therapy. These markers include variants in a key drug metabolizing gene called cytochrome P450 3A4 and a PPARG-coactivator known as PPARGC1B. Other markers were located in genes associated with PPARG function and include the protein kinase MAP2K6, a potassium inwardly-rectifying channel called KCNJ16, and the farnesoid X receptor (NR1H4).
Together, these markers predicted both response to Actos therapy and improvement in insulin sensitivity in the patients taking the drug.
Dr. DiStefano said the next steps in this research will be to characterize the functional effects of the polymorphisms and assess the effect of these variants in other patients.
"This work may help treat the right people with the right drug, design better drugs that will effectively improve insulin sensitivity for more people, and possibly safeguard against adverse side reactions seen with some members of this drug class," she said. Importantly, these findings will enable us to dissect the pharmacogenetics of TZD response, which will expand our understanding of the genetic determinants of insulin resistance and its treatment, provide critical baseline information for the development and implementation of genetic screening into the therapeutic decision making process, and lay the foundation for "individualized medicine" for patients with T2D.
Other TGen scientists involved in the study were: Investigator Dr. David W. Craig and Research Associate Kimberly A. Yeatts.
Researchers from USC were: Drs. Anny H. Xiang, Thomas A. Buchanan and Richard M. Watanabe, and graduate student Mohamad T. Hassanein.
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
The Translational Genomics Research Institute (TGen)
Personalized medicine involves the rapid application of laboratory discoveries to therapies, depending on the individual genetic make-up of each patient.
A TGen-led team, working with scientists from the University of Southern California's Keck School of Medicine, investigated why as many as 30-40 percent of diabetes patients treated with thiazolidinediones (TZDs), such as Actos, fail to respond to the drug with the expected improvement in insulin sensitivity.
TZDs are a class of insulin-sensitizing drugs used to treat type 2 diabetes mellitus (T2DM). TZDs are agonists for the nuclear receptor peroxisome proliferator-activated receptor-g (PPARG). Although the exact mechanism by which TZDs act is not yet known, data indicate that TZDs improve insulin sensitivity by direct and indirect effects on adipose tissue and muscle. TZD therapy can significantly lower diabetes incidence in at-risk subjects, suggesting this treatment may be an effective means to prevent the disease.
Previously, TGen and Keck investigators found that genetic variations in the PPARG gene were associated with TZD metabolism and the biological effects of TZD, and thereby contribute to the therapeutic response associated with TZD. However, these variants did not fully account for the non-response rate, suggesting that other variants may contribute to TZD response.
To identify other variants that predict response to TZDs, TGen researchers performed a genome-wide analysis of 115,352 single nucleotide polymorphisms, or SNPs (a DNA sequence variation within the more than 3 billion base pairs in the human genome). In addition, the scientists also systematically screened 28 key genes involved in TZD metabolism or PPARG-stimulated pathways.
Of the markers examined, DiStefano and her team identified five critical markers that may predict response to TZD mono-therapy. These markers include variants in a key drug metabolizing gene called cytochrome P450 3A4 and a PPARG-coactivator known as PPARGC1B. Other markers were located in genes associated with PPARG function and include the protein kinase MAP2K6, a potassium inwardly-rectifying channel called KCNJ16, and the farnesoid X receptor (NR1H4).
Together, these markers predicted both response to Actos therapy and improvement in insulin sensitivity in the patients taking the drug.
Dr. DiStefano said the next steps in this research will be to characterize the functional effects of the polymorphisms and assess the effect of these variants in other patients.
"This work may help treat the right people with the right drug, design better drugs that will effectively improve insulin sensitivity for more people, and possibly safeguard against adverse side reactions seen with some members of this drug class," she said. Importantly, these findings will enable us to dissect the pharmacogenetics of TZD response, which will expand our understanding of the genetic determinants of insulin resistance and its treatment, provide critical baseline information for the development and implementation of genetic screening into the therapeutic decision making process, and lay the foundation for "individualized medicine" for patients with T2D.
Other TGen scientists involved in the study were: Investigator Dr. David W. Craig and Research Associate Kimberly A. Yeatts.
Researchers from USC were: Drs. Anny H. Xiang, Thomas A. Buchanan and Richard M. Watanabe, and graduate student Mohamad T. Hassanein.
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
The Translational Genomics Research Institute (TGen)
Diabetes Current Events and Diabetes News RSSResearch sheds light on workings of anti-cancer drug
The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.
Hormone ghrelin can boost resistance to Parkinson's disease
Ghrelin, a hormone produced in the stomach, may be used to boost resistance to, or slow, the development of Parkinson's disease, Yale School of Medicine researchers report in a study published in a recent issue of the Journal of Neuroscience.
Diabetes cases to double and costs to triple by 2034
In the next 25 years, the number of Americans living with diabetes will nearly double, increasing from 23.7 million in 2009 to 44.1 million in 2034.
Flaxseed oil and osteoporosis
Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health.
Diabetes surgery summit consensus lays foundation for new field of medicine
A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery.
ESC to give talks on Diabetes in three cities in China
As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou.
New research shows versatility of amniotic fluid stem cells
For the first time, scientists have demonstrated that stem cells found in amniotic fluid meet an important test of potential to become specialized cell types, which suggests they may be useful for treating a wider array of diseases and conditions than scientists originally thought.
First reconstitution of an epidermis from human embryonic stem cells
Stem cell research is making great strides. This is yet again illustrated by a study carried out by the I-STEM* Institute (I-STEM/ Inserm UEVE U861/AFM), published in the Lancet on 21 November 2009. The I-STEM team, directed by Marc Peschanski has just succeeded in recreating a whole epidermis from human embryonic stem cells.
An atomic-level look at an HIV accomplice
Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity.
Scripps research scientists find new link between insulin and core body temperature
A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature.
More Diabetes Current Events and Diabetes News Articles
 |
The First Year: Type 2 Diabetes: An Essential Guide for the Newly Diagnosed (First Year, The) by Gretchen Becker (Author), Allison B. Goldfine (Foreword) After Gretchen Becker was diagnosed with type 2 diabetes in 1996, she educated herself on every aspect of this chronic condition — by reading medical and scientific books and journals, talking with doctors and listening to her own body. In 2001, she marshaled everything she had learned as a "patient-expert" into the first edition of this book, which she has now completely updated and revised. The First Year®—Type 2 Diabetes uniquely guides you step-by-step through your first year with diabetes, walking you through everything you need to learn and do each day of your first week after diagnosis, each subsequent week of the first month, and each subsequent month of the crucial first year. In clear, concise, accessible language, Becker covers a wide range of practical, medical, and... |
 |
Diabetes For Dummies (For Dummies (Health & Fitness)) by Alan L. Rubin MD (Author) Covers the latest glucose meters and insulin treatments The straight facts on treating diabetes successfully and living a full life Want to know how to manage diabetes? Leading diabetes expert Dr. Alan Rubin gives you reassuring, authoritative guidance in putting together a state-of-the-art treatment program. You'll learn about all the advances in monitoring glucose, the latest medications, and how to develop a diet and exercise plan to stay healthy. You'll also see how to overcome insurance and on-the-job obstacles. Discover how to: Reduce your diabetes risk Understand the different types of diabetes Manage diabetes in children and the elderly Prevent long-term complications Get the support you need |
 |
Diabetes Health Pack-Nature Made Multivitamin & Mineral Supplement, 60 Packets by Nature Made Nature Made® Diabetes Health Pack provides essential nutrients that may be lacking due to the strain diabetes can often put on the bodys health. Each pack provides a complete, full potency formulation of vitamins, minerals and alpha lipoic acid. |
 |
The Official Pocket Guide to Diabetic Exchanges by American Diabetes Association (Author) Every day, every meal, millions and millions of people count on the world-famous Exchange Lists for Meal Planning to make sure they're choosing the right kinds of foods and portion sizes from the various food groups. Now people with diabetes can take the Exchange Lists with them to the grocery store or to restaurants with the Official Pocket Guide to Diabetic Exchanges. Measuring just 3.5" x 6", this little powerhouse is jam-packed with the exact same information found in the standard exchange lists, yet it fits conveniently into a purse or coat pocket. |
 |
Blood Sugar 101: What They Don't Tell You About Diabetes by Jenny Ruhl (Author) Based on the award winning Bloodsugar101.com web site, this book explains what peer-reviewed research published in top medical journals has to say about: What is a normal blood sugar? How does diabetes develop? What really causes diabetes? What blood sugar levels cause complications? Must you deteriorate? What diet is right for you? How can you make that diet work? What medications are safe? What supplements lower blood sugar? Written in clear and understandable language, this book provides all the tools needed to understand how blood sugar works and achieve blood sugar health. |
 |
Betty Crocker's Diabetes Cookbook: Everyday Meals, Easy as 1-2-3 by Betty Crocker Editors (Author) At last! This special cookbook puts flavor and choice back on the menu for people with diabetes and their families Betty Crocker, America's most trusted friend in the kitchen, has teamed up with the International Diabetes Center (IDC)--one of the leading medical centers--to create an indispensable source of easy-to-make recipes and up-to-the-minute food and nutrition information for the growing numbers of people who have diabetes, more than 15 million of them. Here is the first cookbook to include recipes featuring Carbohydrate Choices--the new, simplified approach to meal planning recommended by the American Diabetes Association. For people who find diet exchanges too hard, too limiting or too much work, this new method is a real breakthrough. Each of the book's 140 recipes... |
 |
Medport Diabetes Travel Organizer From GMS Holds Two Weeks Supplies/ Will Hold Syringes,vials Pens Secure(well Constructed ,One of the Nicest Diabetic Travel Bags on the Market) a Great Value - Cools for up to 18 Hrs Comes with 2-6 Oz Polar Tech Gel Paks by Medport Holds enough supplies for up to two weeks. Cool side carries insulin and MED IceTM. Room temperature side carries meter and supplies. Detachable medical waste pouch provides a safe alternative to store medical waste until properly disposed. Convenient handy carry strap. Includes two MED IceTM refreezable ice packs. Measures 9 in. x 6 in. x . This item only available in black. |
 |
Dr. Bernstein's Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugars by Richard K. Bernstein (Author) The standard text on living with diabetes, newly revised and updated with all the latest scientific findings. Since its first publication in 1997, DR. BERNSTEIN'S DIABETES SOLUTION has become the treatment of choice in the medical field. In this revised and updated edition of his work, Dr. Bernstein provides an accessible, detailed guide to his revolutionary approach to normalizing blood sugars and thereby preventing or reversing long-term complications of diabetes. He offers the most up-to-date information on new products, medications, and supplements, and outlines a plan to reverse the obesity that underlies most cases of Type II diabetes. Dr. Bernstein discusses breakthrough science and potential cures, and has added information on the new insulins and insulin ... |
 |
The 4-Ingredient Diabetes Cookbook: Simple, Quick, and Delicious Recipes Using Just 4 Ingredients or Less by Nancy Hughes (Author) |
 |
Tell Me What to Eat If I Have Diabetes: Nutrition You Can Live With by Elaine Magee (Author) Just because you have diabetes doesn't mean you can't enjoy life, eat well, and live healthy! Tell Me What to Eat If I Have Diabetes begins with a detailed, but non-technical overview of diabetes, specifically Type II diabetes. Elaine clearly presents the latest medical findings on what causes diabetes, available treatments, and the dietary implications of this disease. This revised edition of Tell Me What to Eat If I Have Diabetes includes: * How to use an individualized carbohydrate budget. * Practical tips to lower dangerous blood lipids. * Quick guide to understanding and using the glycemic index and glycemic load. * Revolutionary fiber tips (because you can't talk about carbohydrates, Type II diabetes, and great health without factoring in... |
| © 2009 BrightSurf.com |